New Therapeutics for Diabetes Using Incretin Hormone / 대한내과학회지
Korean Journal of Medicine
;
: 625-634, 2011.
Article
in Korean
| WPRIM
| ID: wpr-201155
ABSTRACT
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors). The former is resistant to DPP-4 and injectable. The latter is oral medications raising endogenous GLP-1 by inhibiting the degrading enzyme DPP-4. The incretin based therapies are promising and more commonly used due to their action and safety profile. Stimulation of insulin secretion by these drugs occurs in a glucose-dependent manner. Incretin based therapies have low risk for hypoglycemia. The subsequent review outlines evidence from selected clinical trials of the currently available GLP-1 agonists, exenatide and liraglutide, and DPP-4 inhibitors, sitagliptin and vildagliptin.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Peptides
/
Pyrazines
/
Pyrrolidines
/
Triazoles
/
Venoms
/
Adamantane
/
Receptors, Glucagon
/
Glucagon-Like Peptide 1
/
Dipeptidyl-Peptidase IV Inhibitors
/
Incretins
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS